May 22, 2013

Save Email Print Bookmark and Share
A A
Reporter: AP Email

FDA Warns of Drugs in Reumofan Dietary Supplements

WASHINGTON (AP) - The Food and Drug Administration is warning consumers not to use Reumofan dietary supplements, after receiving reports of bleeding, stroke and death among people taking the pills.

Reumofan Plus and Reumofan Plus Premium are marketed as natural remedies for arthritis and muscle pain, but the FDA says the products actually contain several prescription drugs. A chemical analysis by the agency found that Reumofan Plus contains three drugs, including the muscle relaxant methocarbomal and the anti-inflammatory drug dexamethasone. These drugs can interact with other medications, causing life-threatening side effects in some patients.

The FDA first warned consumers about the products in June, but says complications have continued to be reported.

Reumofan products are manufactured in Mexico by Riger Naturals and sold in the U.S. at retail shops and over the Internet.


Comments are posted from viewers like you and do not always reflect the views of this station.
powered by Disqus

Exercise & Fitness News

  • Heat Cramps
    Title: Heat Cramps
    Category: Diseases and Conditions
    Created: 8/4/1999 4:30:00 AM
    Last Editorial Review: 5/21/2013 12:00:00 AM
  • Drinking Too Much Water While Exercising Can Be Dangerous
    Title: Drinking Too Much Water While Exercising Can Be Dangerous
    Category: Doctor's Views
    Created: 6/1/2005 12:00:00 AM
    Last Editorial Review: 5/21/2013 12:00:00 AM
  • Health Tip: Run Smart, Run Safe
    Title: Health Tip: Run Smart, Run Safe
    Category: Health News
    Created: 5/21/2013 8:35:00 AM
    Last Editorial Review: 5/21/2013 12:00:00 AM
  • Heat Stroke
    Title: Heat Stroke
    Category: Diseases and Conditions
    Created: 8/4/1999 4:30:00 AM
    Last Editorial Review: 5/14/2013 12:00:00 AM
  • Health Tip: Keep Your Family Fit
    Title: Health Tip: Keep Your Family Fit
    Category: Health News
    Created: 4/30/2013 8:35:00 AM
    Last Editorial Review: 4/30/2013 12:00:00 AM